AOBiome Therapeutic, LLC products

We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled clinical trials evaluating both topical and intranasal routes of delivery of AOB with treatment durations ranging from two to 12 weeks. Regardless of dose, mode of delivery, indication targeted, or age of patients, our bacterial drug candidate B244 has been very well tolerated with an adverse event profile that is equal to or less than the vehicle.

The human microbiome consists of hundreds of trillions of microorganisms, outnumbering human cells by 10 to 1 with as many as 3 million bacterial genes to our approximately 20 thousand. While the microbiome has recently become an area of active research, its overall effects on human health remain largely unknown.